The Latest Cardiac and Vascular News
DENVER–(BUSINESS WIRE)–Several Medicare Administrative Contractors (MACs) have officially approved Artificial Intelligence-enabled Quantitative Coronary Topography (AI-QCT) scans for Medicare recipients with stable and acute symptoms suspicious of coronary artery disease. Cleerly, the company on a mission to eradicate heart attacks, requested the decision on MAC coverage in February of 2023 to expand […]
New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier SAN FRANCISCO – September 4, 2024 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Cleerly, the company working to create a new standard of care for the diagnosis of heart […]
DENVER–(BUSINESS WIRE)–Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. The study describes the validation of Cleerly’s artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification. In two trials,1-2
DENVER–(BUSINESS WIRE)–Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Coronary Artery Disease (CAD) Staging System. The CAD Staging System is a […]
DENVER–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Food and Drug Administration (FDA)-cleared Cleerly ISCHEMIA software device applied to a non-invasive coronary CT angiogram (CCTA) can be billed using the new Category I CPT® code 75580. The American […]
Study Results Demonstrate the Prominent Effects of Cleerly’s Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease DENVER – February 8, 2024 — Cleerly, the company working to create a new standard of care to aid in the diagnosis of heart disease, announced continued strong scientific evidence supporting […]
DENVER–(BUSINESS WIRE)–Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the launch of Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance. Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool, intended […]
DENVER – November 11, 2023 – Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to […]
DENVER–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, is proud to announce its selection as the winner of the Best Use of AI in Health Tech Award presented by The Digital Health Hub Foundation in the Best in Class track at the 2023 HLTH conference, […]
Denver – July 25, 2023 — Cleerly, the company creating a new standard of care for heart disease, announced it will be presenting as a Diamond Partner at the Society of Cardiovascular Computed Tomography’s (SCCT) Annual Scientific Meeting, July 27-30 in Boston, MA at the Hynes Convention Center. Onsite, Cleerly executives […]
